Get Premium to unlock powerful stock data
NAS:BMRN (USA)   Healthcare » Biotechnology
Biomarin Pharmaceutical Inc logo

Biomarin Pharmaceutical Inc $ 90.22 0 (0%)

On watch
Avg Vol (1m):
Market Cap $:
16.56 Bil
Enterprise Value $:
16.57 Bil
PE Ratio:
PB Ratio:
Warning! GuruFocus has detected 1 Severe warning sign with BMRN. Click here to check it out.
10Y: -% Above Low: +NaN% Below High: NaN%
PE Ratio P/S Ratio P/B Ratio Price-FCF Ratio Market Cap
Current and historical daily P/E ratio for Biomarin Pharmaceutical Inc () from 1999 to Jan 17 2022. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The P/E ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the P/E ratio is positive. Also for stocks with the same P/E ratio, the one with faster growth business is more attractive. Biomarin Pharmaceutical stock (BMRN) PE ratio as of Jan 17 2022 is 1127.75. More Details

Biomarin Pharmaceutical PE Ratio (TTM) Chart


Biomarin Pharmaceutical PE Ratio (TTM) Historical Data

Total 1217
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 14
Biomarin Pharmaceutical PE Ratio (TTM) Historical Data
Date PE Ratio (TTM) Data Date PE Ratio (TTM) Data
2022-01-17NaN 2021-11-15NaN
2022-01-14NaN 2021-11-12NaN
2022-01-13NaN 2021-11-11NaN
2022-01-12NaN 2021-11-10NaN
2022-01-11NaN 2021-11-09NaN
2022-01-10NaN 2021-11-08NaN
2022-01-07NaN 2021-11-05NaN
2022-01-06NaN 2021-11-04NaN
2022-01-05NaN 2021-11-03NaN
2022-01-04NaN 2021-11-02NaN
2022-01-03NaN 2021-11-01NaN
2021-12-31NaN 2021-10-29990.4
2021-12-30NaN 2021-10-28977.5
2021-12-29NaN 2021-10-27896.5
2021-12-28NaN 2021-10-26917.8
2021-12-27NaN 2021-10-25918.9
2021-12-24NaN 2021-10-22921.8
2021-12-23NaN 2021-10-21938.5
2021-12-22NaN 2021-10-20939.4
2021-12-21NaN 2021-10-19926.8
2021-12-20NaN 2021-10-18924.0
2021-12-17NaN 2021-10-15948.6
2021-12-16NaN 2021-10-14969.0
2021-12-15NaN 2021-10-13960.3
2021-12-14NaN 2021-10-12982.9
2021-12-13NaN 2021-10-11973.8
2021-12-10NaN 2021-10-08972.9
2021-12-09NaN 2021-10-07964.3
2021-12-08NaN 2021-10-06973.4
2021-12-07NaN 2021-10-05959.1
2021-12-06NaN 2021-10-04948.5
2021-12-03NaN 2021-10-01964.5
2021-12-02NaN 2021-09-30966.1
2021-12-01NaN 2021-09-29959.9
2021-11-30NaN 2021-09-28964.8
2021-11-29NaN 2021-09-2718.3
2021-11-26NaN 2021-09-2418.3
2021-11-25NaN 2021-09-2318.5
2021-11-24NaN 2021-09-2218.4
2021-11-23NaN 2021-09-2118.2
2021-11-22NaN 2021-09-2018.0
2021-11-19NaN 2021-09-1718.1
2021-11-18NaN 2021-09-1617.8
2021-11-17NaN 2021-09-1518.0
2021-11-16NaN 2021-09-1417.8

Biomarin Pharmaceutical PE Ratio (TTM) Comparison

Company Market Cap(Mil) PE Ratio (TTM)

Business Description

Biomarin Pharmaceutical Inc logo

Business Description

Healthcare » Biotechnology » NAICS : 325412 SIC : 2834
770 Lindaro Street, San Rafael, CA, USA, 94901
BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU (in addition to long-standing U.S. rights, BioMarin has reacquired international rights for Kuvan and Palynziq from Merck KGaA). Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) is poised to potentially launch in the 2022-23 timeframe.